Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin
The goal of this clinical trial is to learn how atorvastatin in patients with advanced high grade serous cancer of the ovary, fallopian tube, or peritoneum changes the tumor immune environment. The main question it aims to answer is:
- Does atorvastatin combined with standard of care chemotherapy and surgery changes the number of tumor-promoting macrophages in the tumor microenvironment
- Researchers will compare standard of care chemotherapy and surgery to see if there is a difference in tumor promoting macrophages.
- Participants will take atorvastatin (daily pill) alongside their standard treatment.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Colorado
-
Aurora、Colorado、美国、80045
- University of Colorado Anschutz
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Be a patient with ovarian cancer aged 18-89
- Diagnosed via tissue biopsy not ascites
- For persons of reproductive potential, use of highly effective method(s) of contraception.
- Patients with primary Stage III/IV high-grade serous ovarian/fallopian tube/primary peritoneal cancer not amenable to upfront cytoreductive surgery.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.
- Absolute Neutrophil Count 1500 cells/mL
- Platelet count > 100,000 mL.
- Hemoglobin 9.0 g/dL
- Serum albumin ³ 2.5 g/dL.
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN).
- aspartate aminotransferase (AST )and alanine aminotransferase (ALT) ≤ 3.0 x ULN.
- Serum creatinine ≤ 1.5x ULN
Exclusion Criteria:
- Inability to comply with study and follow-up procedures.
- Significant cardiovascular disease, such as New York Heart Association cardiac disease (class II or greater), myocardial infarction within the past 3 months, unstable arrhythmia, or unstable angina.
- Known clinically significant liver disease defined as AST and ALT > 3.0 x ULN and/or total bilirubin ≥ 1.5 x ULN, or documented history of active viral, alcoholic, or other hepatitis, cirrhosis, and inherited liver disease.
- Participation in investigational clinical trial within last 30 days.
Medical history of untreated HIV infection. Patients with medical history of HIV infection are eligible provided they meet following criteria
- Are stable on antiretroviral therapy for ≥4 weeks before randomization
- Agree to adhere to antiretroviral therapy per World Health Organization (WHO) guidelines
- Have no documented multi-drug resistance that would prevent effective antiretroviral therapy
- Have a viral load of <400 copies per mL at screening
- Have CD4+ T cell count at ≥ 350 cells per μL
- Have no history of acquired immunodeficiency syndrome (AIDS) -defining opportunistic infection ≤ 12 months before randomization.
- Inability to provide informed consent.
- Known central nervous system (CNS) malignancy or CNS metastases.
- Patients with previous malignancy within the past 2 years from cycle 1, day 1, except those with negligible risk of metastasis or death, such as adequately controlled basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the breast.
- History of stroke or transient ischemic attack (TIA) within 3 months prior to cycle 1 day 1(C1D1).
- Patients with prognosis for survival less than 6 months.
- Patients deemed otherwise clinically unfit for clinical trial per Investigator's discretion.
Patients with duodenal stent or other gastrointestinal (GI) disorder/defect that would interfere with absorption of oral medication.
o Includes patients unable to swallow orally administered medication and patients with GI disorders likely to interfere with absorption of the study medication
- Female patients who maintain fertility potential and refuse to comply to use contraception and be followed for pregnancy by pregnancy testing.
- Patients who are currently pregnant or lactating.
- Prior or current statin use that would prohibit randomization into SOC arm.
- Planned treatment with bevacizumab in the primary treatment setting.
- Diagnosis based on ascites assessment only and not a tissue biopsy.
- Patients deemed otherwise clinically unfit for clinical trial per investigators discretion
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Standard of Care
neoadjuvant chemotherapy with 3-4 cycles of carboplatin/paclitaxel, interval debulking surgery, then 2-3 additional cycles of chemotherapy with carboplatin/paclitaxel
|
neoadjuvant chemotherapy with 3-4 cycles of carboplatin/paclitaxel, interval debulking surgery, then 2-3 additional cycles of chemotherapy with carboplatin/paclitaxel
|
|
实验性的:Atorvastatin with Standard of Care
Patients in this arm will take atorvastatin daily alongside neoadjuvant chemotherapy with 3-4 cycles of carboplatin/paclitaxel, interval debulking surgery, then 2-3 additional cycles of chemotherapy with carboplatin/paclitaxel
|
Neoadjuvant chemotherapy with carboplatin and paclitaxel in addition to daily atorvastatin, interval debulking surgery, then 2-3 additional cycles of carboplatin and paclitaxel
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline of CD163+ tumor associated macrophages in post-treatment specimens.
大体时间:3 months
|
The primary efficacy endpoint is the change from baseline to the post-treatment surgical specimen in the mean CD163 H-score among CD68-positive tumor-associated macrophages.
CD68 and CD163 expression will be assessed by multispectral immunohistochemistry in paired pre-treatment biopsy and post-treatment surgical samples.
|
3 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression free survival
大体时间:5 years
|
Investigator-assessed progression-free survival will be defined as the time from randomization to the first documented occurrence of objective disease progression or death from any cause, whichever occurs first.
|
5 years
|
|
Overall Survival
大体时间:5 years
|
Overall survival as defined by the time of randomization to time of death from any cause.
|
5 years
|
合作者和调查者
调查人员
- 首席研究员:Nicole Marjon, MD, PhD、CU Anschutz
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 26-0543
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.